Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

Katrine Prætorius, Daniel P Henriksen, Johannes M Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A Andersson, Louise Klokker Madsen, Bo L Chawes

9 Citationer (Scopus)

Abstract

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences https://bit.ly/3pK9Nf9.

OriginalsprogEngelsk
Artikelnummer 00306-2021
TidsskriftERJ Open Research
Vol/bind7
Udgave nummer3
ISSN2312-0541
DOI
StatusUdgivet - aug. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma'. Sammen danner de et unikt fingeraftryk.

Citationsformater